Height and clinical course of Duchenne muscular dystrophy
β Scribed by Coakley, J. H. ;Griffiths, R. D. ;Edwards, R. H. T.
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 105 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0148-7299
No coin nor oath required. For personal study only.
β¦ Synopsis
We think that the article by contains inaccurate and misleading information. The first important criticism is the title, which implies that longitudinal data on the clinical course of the disease are to be presented. This can only be measured by observation over a period of time, and no such data were shown in the paper. The second important criticism is that from the data given in the paper, it would not be possible to repeat the study. We are not told how height was measured (e.g., by tape measure, stadiometer, or anthropometer) or whether allowances were made for contractures or scoliosis in the older boys. Of the 111 boys evaluated, only 92 had their height measured. What happened to the remaining 19? The bald statement that height was corrected for age is not good enough in so potentially important an article: neither the manner of correction nor a reference justifying its use is given. The most unconvincing part of the paper is the claim to demonstrate a significant relationship between height and severity of dystrophy. There is, unsurprisingly, a correlation between age and Vignos scale and also between two age-dependant variables, height and weight, and Vignos scale. The correlation coefficient for age and severity is 0.761, which is not unexpected. If height were a major determinant of disease severity, one would expect that with age eliminated, the correlation coefficient for corrected height and disease severity would be greater rather than less. In fact, the coefficient was only 0.352, which is a very poor correlation. The fact that the P value is less than .05 simply shows that one can be 95% certain that the poor correlation is not a chance observation. Incidentally, we are pleased that the authors have
π SIMILAR VOLUMES
A double-blind controlled trial of penicillamine and vitamin E against placebo was conducted in 106 boys with Duchenne muscular dystrophy. Nine dropped out of the study after being randomized. Patients were evaluated using an established protocol that measures muscle strength, joint contractures, fu
Recent advances in molecular genetics have led to the isolation of the gene defective in patients with Duchenne and Becker's muscular dystrophy and the characterization of its protein product, dystrophin. In this communication, the developments culminating in the identification of the Duchenne muscu
Motor neuron abnormalities have been implicated in the pathogenesis of Duchenne muscular dystrophy. Evidence concerning the effect of injury on motor neurons of human Duchenne muscular dystrophy (DMD) is lacking. We report a DMD patient having, in addition, an obstetric paresis on his left arm. EMG
Duchenne muscular dystrophy (DMD) is a progressive and lethal neuromuscular disorder caused by a defective gene on the X chromosome. There is no effective treatment and the biochemical defect is yet unknown. Mapping of the DMD locus to band Xp21 in the short arm of the X chromosome has given rise to